Jaume Mora, MD, PhD: Naxitamab Approval for High-Risk Neuroblastoma in the Bone or Bone Marrow

Recently, the FDA approved naxitamab in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for patients with relapsed/refractory high-risk neuroblastoma in the bone or bone marrow. In this interview, Jaume Mora, MD, PhD, Scientific Director of Oncology and Hematology at Sant Joan de Déu Barcelona Children's Hospital and lead investigator of one of the trials on which the approval was based, speaks with i3 Health about the benefits of naxitamab for patients with relapsed/r...
Continue reading

Naxitamab Plus GM-CSF Approved For R/R High-Risk Neuroblastoma in Bone or Bone Marrow

The FDA has approved naxitamab (Danyelza®, Y-mAbs Therapeutics, Inc.) plus granulocyte-macrophage colony-stimulating factor (GM-CSF) for pediatric patients aged one year and older and for adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have experienced a partial or minor response to prior therapy, or who have stable disease. The approval was based on two open-label clinical trials, Study 201 and Study 12-230. "Neuroblastoma is a rare cancer but r...
Continue reading

In High-Risk Neuroblastoma, Tandem Transplant Is Superior

A randomized clinical trial reports that in patients with neuroblastoma, tandem autologous stem cell transplant improves outcomes compared with single transplant. Neuroblastoma, a malignancy of the developing sympathetic nervous system, is responsible for around 10% to 12% of childhood cancer deaths. For the 43% of patients who present with high-risk disease, which involves either widespread metastasis in patients over the age of 18 months and/or amplification of the MYCN oncogene, the standard ...
Continue reading

JMJD6 Identified as a Neuroblastoma Tumorigenic Factor

Researchers have identified the JMJD6 gene as a critical factor for neuroblastoma tumorigenesis, indicating potential for a new targeted drug therapy treatment strategy. The most prevalent solid tumor in early childhood cancers, neuroblastoma comprises 15% of total childhood cancer deaths. Neuroblastoma is distinctive from adult cancers in that it is characterized by frequent chromosome copy number variations, and its most prominent features are gene deletion, amplification, or gain. While chrom...
Continue reading

Antibody-Drug Conjugate Is Powerful Against Neuroblastoma

Researchers at the Cancer Center of Children's Hospital of Philadelphia (CHOP) have developed an antibody-drug conjugate (ADC) that is powerfully effective against mouse models of neuroblastoma expressing wild-type and mutant anaplastic lymphoma kinase (ALK). Neuroblastoma, a cancer of the peripheral nervous system typically found in children younger than 5, is the third most common pediatric cancer and the most common cancer in infants. It accounts for over 10% of all childhood cancer-related d...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.

Cron Job Starts